Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes
1Division of Cardiology, University Hospital, Zurich, Switzerland. topole@ccf.org
Insights
Diabetic patients with coronary artery disease benefit significantly from aggressive antithrombotic therapy and percutaneous coronary intervention. However, they still face a higher risk of repeat procedures, necessitating further research into advanced treatments.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Interventional Cardiology
Background:
- Diabetes mellitus is associated with inflammation and a prothrombotic state, increasing the risk of coronary artery disease.
- Diabetic patients experiencing non-ST-segment elevation acute coronary syndromes face a heightened risk of future cardiovascular events.
Purpose of the Study:
- To review the pathophysiologic mechanisms of diabetes-related coronary disease.
- To evaluate the benefits of aggressive antithrombotic therapy and percutaneous coronary intervention in diabetic patients.
- To identify areas for improvement in managing diabetic patients undergoing revascularization.
Main Methods:
- Review of current literature on diabetes, coronary artery disease, and interventional cardiology.
- Analysis of antithrombotic strategies and their efficacy in diabetic populations.
- Assessment of outcomes following percutaneous coronary intervention, including the role of drug-eluting stents.
Main Results:
- Diabetic patients experience greater benefits from aggressive antithrombotic therapy, early angiography, and stenting compared to non-diabetic individuals.
- Key antithrombotic agents include aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors, and heparin/low-molecular-weight heparin.
- Despite drug-eluting stents, diabetic patients remain at higher risk for restenosis and repeat revascularization due to excessive neointimal proliferation.
Conclusions:
- Aggressive antithrombotic therapy and percutaneous coronary intervention are crucial for managing diabetic patients with coronary artery disease.
- Further advancements in local drug elution and systemic therapies are required to mitigate neointimal hyperplasia and reduce repeat revascularization rates in this population.
Abstract:
Key pathophysiologic mechanisms of diabetes-related coronary disease include inflammation and a prothrombotic state. In the setting of non-ST-segment elevation acute coronary syndromes diabetic patients are at high risk for subsequent cardiovascular events. At the same time, they derive greater benefit than non-diabetic counterparts from aggressive antithrombotic therapy, early coronary angiography, and stent-based percutaneous coronary intervention. The mainstays of antithrombotic therapy for diabetic patients undergoing percutaneous revascularization include aspirin, clopidogrel, platelet glycoprotein IIb/IIIa receptor antagonists, and heparin or low-molecular-weight heparin. Despite dramatic reduction in restenosis conferred by drug-eluting stents, diabetic patients remain at increased risk for repeat revascularization. More efforts are needed both in terms of local drug elution as well as systemic pharmacologic therapies to further contain the excessive neointimal proliferation that characterizes the diabetic response to vascular injury.
More Related Videos
07:25Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Related Concept Videos
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
